Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to invent breakthrough protein degrader medicines for patients, today announced the closing of a $102 million Series C financing. The round was led by Biotechnology Value Fund...
China-based I-Mab (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet needs—particularly cancers and autoimmune...
Engineering a new class of cell therapy for autoimmune diseases, Kyverna Therapeutics (Kyverna) announced it raised $25 million in a Series A financing from a group of investors, including prominent biotech Gilead. Proceeds will be used to advance their therapeutic...
The Empire Discovery Institute (EDI), a drug discovery and development accelerator in Upstate New York, invites University of Buffalo (UB) researchers and investigators interested in developing pharmaceuticals to apply for project funding and support. Established by...
The U.S. Food and Drug Administration (FDA) has awarded 12 new clinical trial research grants amounting to over $15 million over the next four years. They seek to enhance the development of medicinal products for patients with rare diseases. The grants were awarded to...
Anokion SA, a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced the acquisition of Kanyos Bio, Inc. and the completion of a $40 million Series B financing. Anokion has come a long way, according to...
